Care During Chemotherapy and Beyond
Perjeta™ is the trade name for the generic drug Pertuzumab. In some cases, health
care professionals may use the generic name Pertuzumab when referring to the trade
drug name Perjeta™.
Perjeta™ is an anti-cancer ("antineoplastic" or "cytotoxic") chemotherapy drug.
This medication is classified as an "antineoplastic agent and a monoclonal
antibody". (For more detail, see “How Perjeta™ Works” below).
What Perjeta™ Is Used For:
- Indicated in combination with trastuzumab and docetaxel for the treatment of patients
with HER2-positive breast cancer. HER2 expression must be present for
initiation of Perjeta™ using FDA-approved test.
Note: If a drug has been approved for one use, physicians may elect to use this
same drug for other problems if they believe it may be helpful.
How Perjeta™ Is Given:
- As an infusion into a vein (intravenous, IV) over 60 minutes.
Important things to remember about the side effects of Perjeta™:
- Most people will not experience all of the Perjeta™ side effects listed.
- Perjeta™ side effects are often predictable in terms of their onset, duration, and
- Perjeta™ side effects will improve after therapy is complete.
- Perjeta™ side effects may be quite manageable. There are many options to minimize
or prevent the side effects of Perjeta™.
The following side effects are common (occurring in greater than 30%)
for patients taking Perjeta™. Reactions reported in combination therapy with trastuzumab
These are less common (occurring in 10-29%) side effects for patients
receiving Perjeta™. Reactions reported in combination therapy with
trastuzumab and docetaxe:
Not all side effects are listed above. Side effects that are very rare -- occurring
in less than about 10 percent of patients -- are not all listed here. But you should
always inform your health care provider if you experience any unusual symptoms.
When to contact your doctor or health care provider:
Contact your health care provider immediately, day or night or go to the
emergency room, if you should experience any of the following symptoms:
- Fever of 100.4º F (38º C) or higher, chills (possible signs of infection)
- Signs of a reaction (wheezing; chest tightness; fever; itching; bad cough; blue
or grey skin color; seizures; swelling of the face, lips tongue or throat)
- Trouble breathing
- Chest pain or pressure or a fast heartbeat
The following symptoms require medical attention, but are not an emergency. Contact
your health care provider within 24 hours of noticing any of the following:
- Signs of infection: Fever, chills, very bad sore throat, ear or sinus pain, cough
with or without sputum, pain with passing urine, wounds that will not heal
- Nausea (interferes with ability to eat and unrelieved with prescribed medication)
- Vomiting (vomiting more than 4-5 times in a 24 hour period)
- Diarrhea (4-6 episodes in a 24-hour period)
- Dizziness or lightheadedness
- Bad headache
- Big weight gain
- Unusual bleeding or bruising
- Extreme fatigue (unable to carry on self-care activities)
- Muscle weakness
- Mouth sores (painful redness, swelling or ulcers)
Always inform your health care provider if you experience any unusual symptoms.
- Before starting Perjeta™ treatment, make sure you tell your doctor about any
other medications you are taking (including prescription, over-the-counter, vitamins,
herbal remedies, etc.).
- Do not receive any kind of immunization or vaccination without your doctor’s approval
while taking Perjeta™.
- Inform your health care professional if you are pregnant or may be pregnant prior
to starting this treatment. Pregnancy category D (Perjeta™ may be hazardous to the
fetus. Women who are pregnant or become pregnant must be advised of the potential
hazard to the fetus.)
- For both men and women: Use contraceptives, and do not conceive a child (get pregnant)
while taking Perjeta™. Barrier methods of contraception, such as condoms, are recommended.
Verify pregnancy status prior to treatment initiation. Effective contraception should
be used during therapy and for 6 months after treatment.
- Do not breast feed while taking Perjeta™.
- Drink at least two to three quarts of fluid every 24 hours, unless you are instructed
- You may be at risk of infection so try to avoid crowds or people with colds, and
report fever or any other signs of infection immediately to your health care provider.
- Wash your hands often.
- To help treat/prevent mouth sores, use a soft toothbrush, and rinse three times
a day with 1 teaspoon of baking soda mixed with 8 ounces of water.
- Use an electric razor and a soft toothbrush to minimize bleeding.
- Avoid contact sports or activities that could cause injury.
- To reduce nausea, take anti-nausea medications as prescribed by your doctor, and
eat small, frequent meals.
- Follow regimen of anti-diarrhea medication as prescribed by your health care professional.
- Eat foods that may help reduce diarrhea (see
managing side effects - diarrhea).
- Acetaminophen or ibuprophen may help relieve discomfort from fever, headache and/or
generalized aches and pains. However, be sure to talk with your doctor before taking
- Avoid sun exposure. Wear SPF 15 (or higher) sun block and protective clothing.
- In general, drinking alcoholic beverages should be kept to a minimum or avoided
completely. You should discuss this with your doctor.
- Get plenty of rest.
- Maintain good nutrition.
- Remain active as you are able. Gentle exercise is encouraged such as a daily walk.
- If you experience symptoms or side effects, be sure to discuss them with your health
care team. They can prescribe medications and/or offer other suggestions that are
effective in managing such problems.
Monitoring and Testing:
- Lab work to check blood counts and liver/kidney functions will be checked regularly
by your health care professional while you are taking Perjeta™, to monitor side
effects and check your response to therapy.
- HER2 expression must be present for initiation of Perjeta™ (either as 3+ IHC [Dako
Herceptest™] or FISH amplification ratio >2 [Dako HER2 FISH pharmDx™
- Negative pregnancy test prior to initiation.
- Cardiac studies to assess Left Ventricular Ejection Fracture (LVEF), may be ordered.
How Perjeta™ Works:
Targeted therapy is the result of about 100 years of research dedicated to understanding
the differences between cancer cells and normal cells. To date, cancer treatment
has focused primarily on killing rapidly dividing cells because one feature of cancer
cells is that they divide rapidly. Unfortunately, some of our normal cells divide
rapidly too, causing multiple side effects.
Targeted therapy is about identifying other features of cancer cells. Scientists
look for specific differences in the cancer cells and the normal cells. This information
is used to create a targeted therapy to attack the cancer cells without damaging
the normal cells, thus leading to fewer side effects. Each type of targeted therapy
works a little bit differently but all interfere with the ability of the cancer
cell to grow, divide, repair and/or communicate with other cells.
There are different types of targeted therapies, defined in three broad categories.
Some targeted therapies focus on the internal components and function of the cancer
cell. The targeted therapies use small molecules that can get into the cell and
disrupt the function of the cells, causing them to die. There are several types
of targeted therapy that focus on the inner parts of the cells. Other targeted therapies
target receptors that are on the outside of the cell. Therapies that target receptors
are also known as monoclonal antibodies. Antiangiogenesis inhibitors target the
blood vessels that supply oxygen to the cells, ultimately causing the cells to starve.
Perjeta™ has the component of an antibody type of targeted therapy. Antibodies are
an integral part of the body’s immune system. Normally the body creates antibodies
in response to an antigen (such as a protein or a germ) that has entered the body.
The antibodies attach to the antigen in order to mark it for destruction by the
immune system. To make anti-cancer antibodies in the laboratory, scientists analyze
specific antigens on the surface of cancer cells (the targets). Then using animal
and human proteins, they create a specific antibody that will attach to the target
antigen on the cancer cells. When given to a patient, these antibodies will attach
to matching antigens like a key fits a lock. Since antibodies target only specific
cells, they may cause less toxicity to healthy cells. Monoclonal antibody therapy
is usually only given for cancers in which antigens and the respective antibodies
have been identified already.
Perjeta™ is a monoclonal antibody which targets the surface of the cells human epidermal
growth factor receptor 2 protein (HER2) on the cancer cell, interfering with HER2
causing cancer cell death. Perjeta™ binds to a different area of the HER2 protein
than trastuzumab so that when pertuzumab is combined with trastuzumab, a more complete
blockage of HER2 signaling occurs.
Research continues to identify which cancers may be best treated with targeted therapies
and to identify additional targets for more types of cancer.
Note: We strongly encourage you to talk with your health care professional
about your specific medical condition and treatments. The information contained
in this website is meant to be helpful and educational, but is not a substitute
for medical advice.
Chemocare.com is designed to provide the latest information about chemotherapy to patients and their families, caregivers and friends. For information about the 4th Angel Mentoring Program visit www.4thangel.org